Milestones and Sponsored Research Agreements |
12 Months Ended | |
|---|---|---|
Dec. 31, 2016 | ||
| Research and Development [Abstract] | ||
| Research, Development, and Computer Software Disclosure |
9. Milestones and Sponsored Research Agreements Fortress Biotech, Inc. The Company has a license agreement with the University College London Business PLC (“UCLB”) under which the Company received an exclusive, worldwide license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions. In consideration for the license, the Company made upfront payments totaling $0.1 million and may be required to make future milestone payments totaling up to approximately $22.0 million upon the achievement of various milestones related to regulatory or commercial events. In March 2016, the Company paid UCLB $0.4 million due upon completion of the Phase 1 study for Acute Myeloid Leukemia. In the event that CNDO-109 is commercialized, the Company is obligated to pay to UCLB annual royalties ranging from 3% to 5% based upon various levels of net sales of the product. Under the terms of the license agreement, the Company is allowed to grant sublicenses to third parties without the prior approval of UCLB. In the event that the Company sublicenses CNDO-109 to a third party, the Company is obligated to pay to UCLB all or a portion of the royalties the Company receives from the sub-licensee. Through December 31, 2016, the Company has not sub-licensed CNDO-109 to a third party. Cellvation, Inc. In October 2016, Cellvation entered research funding agreement with the University of Texas in connection with the license for a method and apparatus for conditioning cell populations for cell therapies. In connection with this agreement Cellvation agreed to fund $0.7 million of research quarterly through March 31, 2018. For the twelve months ended December 31, 2016, Cellvation recorded an expense of $0.2 million representing amounts due under this arrangement. Helocyte, Inc. In March 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its PepVax immunotherapy for CMV control in allogeneic stem cell transplant recipients (“PepVax Research Agreement”). The Phase 2 study is additionally supported by grants from the National Institutes of Health/National Cancer Institute (“NCI”). Under the terms of the agreement, Helocyte made an upfront payment to COH of $1.0 million, recorded as sponsored research expense, and will pay COH up to an additional $2.0 million upon the achievement of certain clinical milestones. Unless earlier terminated, the agreement expires upon the delivery of a final study report or December 31, 2018. In February 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its Triplex immunotherapy for CMV control in allogeneic stem cell transplant recipients (“Triplex Research Agreement”). The Phase 2 study is additionally supported by grants from the NCI. Under the terms of the agreement, Helocyte made an upfront payment to COH of $1.0 million, recorded as sponsored research expense, and will pay COH up to an additional $3.4 million upon the achievement of certain clinical milestones. Unless earlier terminated, the agreement expires upon the delivery of a final study report or May 31, 2018. In August 2016, Helocyte made a payment of $2.0 million; $1.0 million in connection with its PepVax Research Agreement and $1.0 million in connection with their Triplex Research Agreement. As of December 31, 2016 and 2015, Helocyte recorded approximately $4.4 million, consisting of $2.4 million in connection with the Triplex Research Agreement and $2.0 million in connection with the PepVax Research Agreement and nil, respectively, in research and development expenses in the Company’s Consolidated Statements of Operations in connection with these agreements. Mustang Bio, Inc. In March 2015, in connection with Mustang’s license with COH for the development of CAR-T, Mustang entered into a Sponsored Research Agreement in which Mustang will fund continued research in the amount of $2.0 million per year, payable in four equal annual installments, over the next five years. For the year ended December 31, 2016 and 2015, Mustang incurred expense of $ 2.0 million $1.5 million, respectively and recorded as research and development expense in the Company’s Consolidated Statement of Operations. |